Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
40.30
+0.81 (2.05%)
Aug 13, 2025, 4:00 PM - Market closed

Bright Minds Biosciences Stock Forecast

Stock Price Forecast

According to 4 professional analysts, the 12-month price target for Bright Minds Biosciences stock ranges from a low of $75 to a high of $93. The average analyst price target of $83.25 forecasts a 106.58% increase in the stock price over the next year.

Price Target: $83.25 (+106.58%)
Analyst Consensus: Strong Buy
Target Low Average Median High
Price $75 $83.25 $85 $93
Change +86.10% +106.58% +110.92% +130.77%
* Price targets were last updated on May 21, 2025.

Analyst Ratings

The average analyst rating for Bright Minds Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Mar '25Apr '25May '25Jun '25Jul '25Aug '25
Strong Buy 113333
Buy 333344
Hold 000000
Sell 000000
Strong Sell 000000
Total 446677

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Initiates
n/a
Buy Initiates n/a n/a Jul 2, 2025
Chardan Capital
Chardan Capital
Strong Buy
Maintains
$80
Strong Buy Maintains $80 +98.51% May 21, 2025
TD Cowen
TD Cowen
Strong Buy
Initiates
n/a
Strong Buy Initiates n/a n/a May 13, 2025
Chardan Capital
Chardan Capital
Strong Buy
Initiates
$80
Strong Buy Initiates $80 +98.51% May 7, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$85
Strong Buy Reiterates $85 +110.92% Feb 19, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.